Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence. Haydek JP, Scott FI. Aliment Pharmacol Ther 2021;54:846-847.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Haydek JP, Scott FI. Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence. Aliment Pharmacol Ther 2021;54:846-847.
PMID: 34425006